NCT02782975 Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants Status COMPLETED Phase PHASE1
NCT02781220 Implications for Management of PET Amyloid Classification Technology in the Imaging Dementia(IDEAS) Trial Status TERMINATED Phase N/A
NCT02778971 Implications for Management of PET Amyloid Classification Technology Status COMPLETED Phase N/A
NCT02778438 A Validation Study of the Novel Application of Telehealth in Clinical Drug Development in Subjects With Mild Cognitive Deficits Status COMPLETED Phase N/A
NCT02772523 Control and Intervention Programme on Alzheimer's Disease Risk Factors Status COMPLETED Phase NA
NCT02772185 Neurostimulation and Cognitive Intervention in Alzheimer's Disease Status UNKNOWN Phase PHASE2/PHASE3
NCT02769000 Low Dose RT to Reduce Cerebral Amyloidosis in Early Alzheimer's Status TERMINATED Phase NA
NCT02767609 Measuring Cerebral Blood Flow Using Pseudo-continuous Arterial Spin Labeling Perfusion Magnetic Resonance Imaging Status COMPLETED Phase NA
NCT02760602 A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease Status TERMINATED Phase PHASE3
NCT02759159 The Study of Mechanism of Alzheimer's Disease Using Acupuncture Based on fMRI Status UNKNOWN Phase NA
NCT02756858 An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease Status COMPLETED Phase PHASE2
NCT02754830 A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD) Status COMPLETED Phase PHASE1
NCT02752750 Longitudinal Quantitative Susceptibility Mapping (QSM) in Alzheimer 's Disease Status UNKNOWN Phase N/A
NCT02750982 Laughter Therapy Effects on Mood, Stress and Self-efficacy in People With Neurological Diseases. Status COMPLETED Phase NA
NCT02742597 Patient-Centred Innovations for Persons With Multimorbidity - Ontario Status COMPLETED Phase NA
NCT02719327 Brain Amyloid and Vascular Effects of Eicosapentaenoic Acid Status COMPLETED Phase PHASE2/PHASE3